Insmed Incorporated (INSM) |
|
25.37 0.12 (0.48%)
|
10-02 16:00 |
|
Open: |
25.25 |
Pre. Close: |
25.25 |
|
High:
|
25.52 |
Low:
|
24.99 |
|
Volume:
|
1,082,854 |
Market Cap:
|
3,648(M) |
|
|
|
Technical analysis |
as of: 2023-10-02 4:51:01 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 32.22 One year: 37.63 |
| Support: |
Support1: 23.64 Support2: 21.2 |
| Resistance: |
Resistance1: 27.59 Resistance2: 32.22 |
| Pivot: |
26.08  |
| Moving Average: |
MA(5): 25.61 MA(20): 26.16 
MA(100): 21.69 MA(250): 20.17 |
| MACD: |
MACD(12,26): 0.5 Signal(9): 0.8 |
| Stochastic oscillator: |
%K(14,3): 15.4 %D(3): 18.5 |
| RSI: |
RSI(14): 53.4 |
| 52-week: |
High: 27.59 Low: 16.04 |
| Average Vol(K): |
3-Month: 1,350 (K) 10-Days: 1,059 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ INSM ] has closed above bottom band by 13.5%. Bollinger Bands are 24% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
25.56 - 25.7 |
25.7 - 25.83 |
|
Low:
|
24.61 - 24.8 |
24.8 - 24.97 |
|
Close:
|
25.1 - 25.37 |
25.37 - 25.62 |
|
Company Description |
|
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey. |
Headline News |
Wed, 27 Sep 2023
Can Insmed Incorporated (INSM) Stock Rise to the Top of Healthcare Sector Wednesday? - InvestorsObserver
Tue, 26 Sep 2023
Insmed To Present at Chardan's 7th Annual Genetic Medicines ... - PR Newswire
Wed, 20 Sep 2023
Insmed Incorporated (NASDAQ:INSM) Given Consensus ... - MarketBeat
Mon, 11 Sep 2023
Suvretta Capital Management LLC Grows Stock Holdings in Insmed ... - MarketBeat
Fri, 08 Sep 2023
Insmed Reports Inducement Grants Under NASDAQ Listing Rule ... - PR Newswire
Wed, 06 Sep 2023
Insmed To Present at the Morgan Stanley 21st Annual Global ... - PR Newswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
144 (M) |
| Shares Float |
142 (M) |
|
% Held by Insiders
|
1.2 (%) |
|
% Held by Institutions
|
109.4 (%) |
|
Shares Short
|
12,440 (K) |
|
Shares Short P.Month
|
10,190 (K) |
Stock Financials |
|
EPS
|
-5.43 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-1.1 |
|
Profit Margin (%)
|
-258.3 |
|
Operating Margin (%)
|
-243.3 |
|
Return on Assets (ttm)
|
-32.9 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
18.3 |
|
Gross Profit (p.s.)
|
1.32 |
|
Sales Per Share
|
1.87 |
|
EBITDA (p.s.)
|
-4.51 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-462 (M) |
|
Levered Free Cash Flow
|
-301 (M) |
Stock Valuations |
|
PE Ratio
|
-4.68 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-23.28 |
|
Price to Sales
|
13.53 |
|
Price to Cash Flow
|
-7.9 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
